Across TCGA pan-cancer cohorts, MORF4L1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MORF4L1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher MORF4L1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MORF4L1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, ESCA, and UCEC are the cancer types where MORF4L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.667	0.963	<.001	28	view →
ESCA	OS	Median	II,III,IV	0.136	0.703	<.001	24	view →
UCEC	DFS	Median	All	1.000	0.625	.008	12	view →
ACC	DFS	Median	All	0.209	0.659	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MORF4L1 tumor-vs-normal RNA expression · all MORF4L1 data types